Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/18/2013

hind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking StatementsThis press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations that it has sufficient resources to fund operations for at least the next 12 months; that it will submit a New Drug Application and Marketing Authorization Application for OMS302 in 2013; that it will be able to market and sell OMS302 in 2014; when it will be able to announce data from its PDE10 Phase 1 program; that it will advance its MASP-2 and PDE7 programs into this clinic this year; that it will conduct two additional Phase 3 clinical trials evaluating OMS103HP, with enrollment in the first trial beginning in the first half of 2013; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 18, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
2. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
3. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
4. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
5. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
6. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
7. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
8. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
9. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
10. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
11. Celsion Corporation Announces $15 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Alpha Source, ... , will be exhibiting for the 13th consecutive ... Medical Instrumentation (AAMI) 2013 Conference and Expo. The ... distribute, and manufacture healthcare technologies. This year’s event ... Beach, California. , The three-day event draws ...
(Date:5/21/2013)... Austin, TX (PRWEB) May 21, 2013 ... and outdoor security solutions, today announced that Genzyme, a ... more units of Door Detective® CL for a multi-use ... already installed in four other Genzyme buildings, this latest ... had with the tailgate detection device improving ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 2013 Bed bugs have become so widespread ... Products, many turn to chemical-based pesticides for help to completely ... environmental risks those solutions present, the company advised the public ... instead. , According to My Cleaning Products, chemical-based pesticides ... to be. It shared that the pests have already developed ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... 2011  The 2011 National Ergonomics Conference and Exposition (ErgoExpo) held ... again the largest annual gathering of ergonomics decision makers and ... and by the last few hours of the show, the ... had already renewed and new exhibitors had signed up for ...
... ReportsnReports adds new market research report , Aseptic Packaging ... the $3.5 billion US aseptic packaging industry. It presents ... 2010, and forecasts for 2015 and 2020 by product ... and pouches, cartons, cups, glass bottles) and market (e.g., ...
... Renowned experts in cord blood collection, processing and transplantation ... its commitment as a worldwide industry leader in developing and ... treating patients.  Dr. Wise Young ... Medical Director.  He will serve in a voluntary ...
Cached Biology Technology:2011 ErgoExpo Attendees' Choice Award Winners Announced During Sold Out Expo; Exhibitor Renewal for 2012 Hits 96% and Counting 22011 ErgoExpo Attendees' Choice Award Winners Announced During Sold Out Expo; Exhibitor Renewal for 2012 Hits 96% and Counting 3ReportsnReports - Aseptic Packaging to 2015 2ReportsnReports - Aseptic Packaging to 2015 3StemCyte Adds World Class Talent to its North America and Global Operations 2StemCyte Adds World Class Talent to its North America and Global Operations 3
(Date:5/20/2013)... resistant to the antibiotic colistin are also commonly ... body, according to a study in mBio ... Society for Microbiology. Cross-resistance to colistin and host ... body against bacterial attack, could mean that patients ... with a crippled immune response. Colistin is a ...
(Date:5/20/2013)... Foundation (NSF) planning grant will help establish the Center ... of the University of Illinois at Urbana-Champaign and Worcester ... be devoted to research in drying moist, porous materials ... paper products; chemical products; textiles; and biopharmaceuticals," said Hao ... and human nutrition and the Illinois site director. , ...
(Date:5/19/2013)... that can grow using hydrogen gas as its sole ... of carbon. Researchers at the University of Massachusetts, ... of the American Society for Microbiology. , "This represents ... says Amit Kumar, a researcher on the study who, ... Lab Group at the university. , Under the leadership ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
... Researchers at the University of Kentucky Markey Cancer Center ... insight into the genetic mechanisms underlying Huntington,s disease and ... (or TNRs) in DNA. , The research, performed ... of toxicology and biochemistry and the Madeline James & ...
... a time when federal and private funds for biomedical research ... in the fight against muscle diseases by announcing grants to ... "Federal support for the type of work ... current economic climate. Simply put, without the support of MDA, ...
... [Brown University] Global warming may exact a toll ... shows that one key constituent of marshes may be ... salt marshes. Despite the stresses associated with global warming, ... a graduate student and salt marsh expert at Brown ...
Cached Biology News:Researchers gain insight into mechanism underlying Huntington's 2'Show me the money!' MDA greenlights grants 2'Show me the money!' MDA greenlights grants 3Climate change may spell demise of key salt marsh constituent 2
... a fast and efficient microplate ... high capacity and reliable design allow ... away time than typical stackers. ... make for a seamless and trouble-free ...
... Rabbit polyclonal to MLF1 Interacting ... for all tested applications). ... corresponding to amino acids 73-83 of ... Entrez Gene ID: 359815 ...
... 25 H 27 N 2 NaO 7 S ... Dark burgundy metallic powder Identity: By IR epsilon ... cm): greater than or equal to 60 x ... or equal to 10.0% lambda max ...
... Stoelting, selects single cells, or clusters, with ... at all, a single cell can be ... is collected into the pipette, and automatically ... microtiter plate. Quixells unique aspiration and expulsion ...
Biology Products: